Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POWER: Panitumumab + Cisplatin/5-FU in Esophageal Cancer
NCT01627379Phase 3Terminated
- Sponsor
- AIO-Studien
- Start
- May 2012
- Primary completion
- May 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of panitumumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by AIO-Studien. Started May 2012; status: terminated.
02
Drugs
panitumumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT01627379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01627379.